Table 4.
COMMUNICATION | |||||||
---|---|---|---|---|---|---|---|
(Written) | (Written) | (Written) | (Verbal) | ||||
Consent forms in other languages OR (95% CI) | Supplementary information about clinical trials, in other languages OR (95% CI) | Any materials to facilitate recruitment into clinical trials, in other languages OR (95% CI) | Professional interpretation services OR (95% CI) | ||||
Type of practicea | |||||||
Solo or group practice | ref | ref | ref | ref | |||
Public community health center/hospital | 0.76 (0.38-1.52) | 1.49 (0.70-3.18) | 0.96 (0.46-2.03) | 7.45 (3.32-16.8)1 | |||
VA, private or community hospital | 0.70 (0.25-1.90) | 0.99 (0.25-3.94) | 1.45 (0.49-4.31) | 3.59 (1.20-10.7)3 | |||
University/teaching hosp/research or cancer institute | 1.11 (0.47-2.58) | 1.35 (0.54-3.37) | 1.14 (0.50-2.64) | 4.22 (1.81-9.87)2 | |||
Number of phase III clinical trialsb | |||||||
≤ 2 phase III trials (ref) | ref | ref | ref | ref | |||
≥3 phase III trials | 0.70 (0.39-1.27) | 1.05 (0.54-2.04) | 0.82 (0.45-1.51) | 1.79 (0.98-3.28) | |||
Percent of Latinas in patient populationb | |||||||
<10% (ref) | ref | ref | ref | ref | |||
≥10% | 2.49 (1.28-4.85)2 | 2.58 (1.24-5.36)3 | 2.50 (1.22-5.13)3 | 1.83 (0.93-3.62) | |||
Percent of patients who are LEPb | |||||||
<10% (ref) | ref | ref | ref | ref | |||
≥10% | 3.13 (1.36-7.19)2 | 2.52 (1.15-5.52)3 | 2.02 (0.98-4.13) | 1.99 (0.92-4.30) |
Analyses adjusted for state
Analyses adjusted for state and practice type
p<0.05
p<0.01
p<0.05